Holen Sie sich die Stockscreener-App
0.00
100.00%
-1.71
Schlusskurs vom Vortag:
$1.71
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$10.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.80M
KGV:
0.00
EPS:
-2.97
Netto-Cashflow:
$-37.18M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$36.30
Aptose Biosciences Inc Stock (APTO) Company Profile
Firmenname
Aptose Biosciences Inc
Sektor
Branche
Telefon
310-849-8060
Adresse
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Vergleichen Sie APTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 10.59M | 0 | -35.80M | -37.18M | -2.97 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-10-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-02-20 | Eingeleitet | Maxim Group | Buy |
| 2020-02-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-16 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-23 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | Eingeleitet | Rodman & Renshaw | Neutral |
Alle ansehen
Aptose Biosciences Inc Aktie (APTO) Neueste Nachrichten
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
(APS) Market Performance Analysis (APS:CA) - news.stocktradersdaily.com
In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML - insights.citeline.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Aptose Biosciences Inc. - Baystreet.ca
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial for AML Treatment - TipRanks
Aptose Provides Clinical Update for Tuspetinib-based Triple Drug Therapy in Tuscany Trial - marketscreener.com
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial - The Manila Times
Breakthrough AML Treatment: Triple Drug Therapy Shows Complete Remission in Patients with Resistant Mutations - Stock Titan
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Comparing Sana Biotechnology (NASDAQ:SANA) & Aptose Biosciences (NASDAQ:APTO) - Defense World
Learn to Evaluate (APS) using the Charts (APS:CA) - news.stocktradersdaily.com
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
(APS) Equity Trading Insights (APS:CA) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
(APS) Investment Strategy and Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Announces Auditor Not Standing for Re-Appointment - The Manila Times
Major Red Flag: KPMG Abandons Aptose Over Complex Financial Instrument Controls - Stock Titan
Aptose Biosciences to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference - Nasdaq
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference - The Manila Times
Aptose Biosciences announces change in accounting firm By Investing.com - Investing.com India
Aptose Biosciences announces change in accounting firm - Investing.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com - Defense World
(APS) Daily Stock Insights (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (TSE:APS) Stock Price Passes Below 200-Day Moving Average – What’s Next? - The AM Reporter
Objective long/short (APS) Report (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
(APS) Technical Data (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences shares to delist from Nasdaq as of April 2 - Yahoo Finance
APTO stock touches 52-week low at $1.86 amid sharp annual decline - Investing.com Australia
APTO stock touches 52-week low at $1.86 amid sharp annual decline By Investing.com - Investing.com South Africa
Stock Market Shakes As Major Firms See Sharp Declines - Finimize
Finanzdaten der Aptose Biosciences Inc-Aktie (APTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):